Ipatasertib

From WikiMD's WELLNESSPEDIA

Chemical structure of Ipatasertib

Ipatasertib is an investigational small molecule inhibitor of the protein kinase B (AKT) pathway, which is being studied for its potential use in the treatment of various types of cancer. It is a targeted therapy designed to interfere with the signaling pathways that promote cancer cell growth and survival.

Mechanism of Action[edit]

Ipatasertib works by inhibiting the activity of the AKT enzyme, which is a key component of the PI3K/AKT/mTOR pathway. This pathway is often dysregulated in cancer, leading to increased cell proliferation and survival. By blocking AKT, ipatasertib aims to reduce tumor growth and enhance the effectiveness of other anticancer therapies.

Clinical Development[edit]

Ipatasertib is currently undergoing clinical trials to evaluate its safety and efficacy in combination with other treatments. It is being tested in various cancers, including breast cancer, prostate cancer, and gastric cancer.

Breast Cancer[edit]

In breast cancer, ipatasertib is being studied in combination with paclitaxel and other chemotherapeutic agents. The focus is on patients with triple-negative breast cancer, a subtype that lacks estrogen receptor, progesterone receptor, and HER2/neu expression.

Prostate Cancer[edit]

For prostate cancer, ipatasertib is being evaluated in combination with abiraterone and prednisone. The trials are targeting patients with metastatic castration-resistant prostate cancer (mCRPC), a form of the disease that no longer responds to hormonal therapy.

Gastric Cancer[edit]

In gastric cancer, ipatasertib is being tested alongside standard chemotherapy regimens. Researchers are investigating its potential to improve outcomes in patients with advanced or metastatic disease.

Side Effects[edit]

The side effects of ipatasertib are similar to those of other targeted therapies and may include diarrhea, rash, nausea, and fatigue. As with any investigational drug, the safety profile is continuously monitored during clinical trials.

Future Directions[edit]

Ongoing research aims to better understand the role of ipatasertib in cancer treatment and to identify biomarkers that predict response to therapy. The ultimate goal is to integrate ipatasertib into personalized treatment regimens that maximize efficacy while minimizing adverse effects.

Related Pages[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Ipatasertib&oldid=6627499"